ReviewFrontiers in public health2025
The global response to HIV/AIDS in sub-Saharan Africa: achievements, challenges, and perspectives for the future.
Review in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Predicting the spatiotemporal evolution of HIV/AIDS in Africa: A retrospective analysis of epidemiological trends.Infectious Disease Modelling · 2026Article
- Negotiating access to comprehensive HIV healthcare: Fear, stigma, and health system constraints in Tamale Metropolis, Ghana.Journal of public health research · 2026Article
- Qualitative Exploration of Healthcare Providers' Perspectives on HIV Service Vulnerability During Funding Disruption in Nigeria.AIDS and behavior · 2026Article
- What shapes the quality of life among older persons living with HIV? A multidimensional assessment from The Aids Support Organisation clinics in Uganda.AIDS research and therapy · 2026Article
- Rural health inequalities in perceived HIV vulnerability and nutritional status: a cross-comparison of rural communities in West and Southern Africa.BMC public health · 2026Article
- Three decades of HIV epidemic dynamics in The Gambia: a comprehensive analysis of prevalence, incidence, and mortality trends, 1990-2024.AIDS research and therapy · 2026Article
- Maintain, not obtain: rethinking HIV care in sub-Saharan Africa in the era of dolutegravir.Frontiers in public health · 2026Article
- Urate dysregulation (hyperuricemia and gout) among people living with HIV: A protocol for a systematic review and meta-analysis.PloS one · 2026Article
- Determinants of HIV testing intentions among heterosexual men in the Bolgatanga Municipality of Ghana: Evidence from the theory of planned behaviour.PLOS global public health · 2026Article
- The microbiota-host metabolic axis in cervical cancer: from homeostatic disruption to mechanisms of therapy resistance.Frontiers in cellular and infection microbiology · 2026Review
- Editorial: Tackling non-communicable diseases and epidemiological transition in low- and middle-income countries.Frontiers in public health · 2026Article
- Clinico-microbiological investigation of factors contributing to suboptimal viral suppression among HIV/AIDS patients on sustained antiretroviral treatment in the upper east region of Ghana.Frontiers in medicine · 2026Article
- Trends, Gaps, and Challenges in Antiviral Resistance: A Bibliometric Analysis and Narrative Synthesis of Key Viruses, Resistance Mechanisms, and Drivers.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over four decades, the global response to HIV/AIDS has transformed the disease into a manageable chronic condition, driven by advances in antiretroviral therapy, global financing, and ambitious targets like the 90-90-90 and 95-95-95 goals. Yet HIV remains a major challenge, especially in sub-Saharan Africa, which bears the highest burden worldwide. While AIDS-related mortality has declined, the number of people living with HIV continues to grow, placing significant strain on health systems and financial resources. Persistent challenges include high rates of new infections, late diagnoses, inequalities in access to care, and barriers faced by key populations. Emerging issues such as drug resistance and declining political commitment risk reversing progress. Investments in HIV have yielded broader benefits for health systems, supporting integration with services for tuberculosis and noncommunicable diseases. This review traces the global HIV response, analyses current epidemiological and economic trends, and highlights strategic priorities to sustain progress. Key strategic directions include reducing costs and expanding access to advanced diagnostics and antiretroviral therapy; prioritizing comprehensive, high-quality care over simplified delivery models that risk compromising diagnostic accuracy and fostering drug resistance; integrating HIV programs with services for other diseases, including noncommunicable diseases; strengthening surveillance and management of HIV drug resistance; and sustaining the visibility of HIV while addressing the needs of marginalized populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.